tbuckley/cabot-search huggingface dataset:
Abstract 4133: Is mitochondrial DNA copy number associated with interval colorectal cancers
Authors: Bharat Thyagarajan, Helene Barcelo, Aasma Shaukat
Journal: Cancer Research (2011)

Abstract Colorectal cancers diagnosed in the interval after a complete colonoscopy (interval colorectal cancers) may occur due to due to rapid tumor growth. We have previously demonstrated that microsatellite instability (MSI) is associated with interval colorectal cancers. Mitochondrial DNA copy number has been shown to be inversely associated with rapid tumor growth in lung and breast cancers. However, the association of mitochondrial DNA copy number with interval colorectal cancers, MSI and survival remains unknown. The aim of our study was to study the association of mitochondrial DNA copy number with interval colorectal cancers, MSI and 5-year survival. We conducted a case-control study of 63 interval and 131 frequency matched non-interval colorectal cancers at the Veterans Administration Medical Center. Interval colorectal cancers were defined as colorectal cancers that developed within 5 years of a complete colonoscopy. Archived tumor specimens were tested for mitochondrial DNA copy number and MSI status. Relative mitochondrial DNA copy number was measured by a quantitative real-time polymerase chain reaction (PCR) assay using two pairs of primers, one specific for amplification of the mitochondria- specific gene (ND1) and another specific for amplification of a nuclear gene (CD3). Multivariable logistic regression was used to evaluate the association between mitochondrial DNA copy number, MSI and interval colorectal cancers. Cox proportional hazards regression was used to evaluate the association between mitochondrial DNA copy number and survival. Median mitochondrial copy number was 5.11 (range 1.4-193). Assay reproducibility, based on 20 samples run in duplicate, was 11%. There was no association between mitochondrial DNA copy number and interval colorectal cancers (OR 0.9; 95% CI 0.66-1.22; p 0.50), but mitochondrial DNA copy number was inversely associated with MSI status (OR 0.32; 95% CI 0.18-0.55; p &amp;lt;.001). There was a trend towards lower overall 5-year survival with lower copy number (HR 0.89; 95% CI 0.74-1.08; p 0.07), and a significantly lower survival with lower copy number among stage IV colorectal cancers (HR 0.53; 95% CI 0.31-0.90; p 0.02). Mitochondrial DNA copy number is inversely associated with MSI and overall survival for colorectal cancer. Low mitochondrial DNA copy number may be a marker of rapid tumor growth and poor survival in colorectal cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4133. doi:10.1158/1538-7445.AM2011-4133
Abstract 3571: UKLS - United Kingdom Lung Cancer Screening Trial
Authors: John K. Field, David Baldwin, Duffy W. Stephen, Anand Devaraj, David M. Hansell
Journal: Cancer Research (2012)

Abstract In the UK 33,500 individuals die from lung cancer each year. The effectiveness of screening pre-symptomatic individuals urgently requires evaluation. The aim of UK Lung cancer Screening trial (UKLS) is to provide data required for an informed decision about the desirability of introducing population screening for lung cancer in the UK. The aim of the UKLS is to demonstrate a 25-30% mortality advantage and cost effectiveness of the screening. The UKLS pilot has started to recruit in 2011. The pilot sites are based at the Liverpool Heath &amp; Chest Hospital, Liverpool and the Papworth Hospital, Cambridgeshire with a second reading site at the Royal Brompton Hospital, London. It will randomise 4,000 high risk patients identified by the Liverpool Lung Project (LLP) Risk Prediction Model. If the pilot trial is successful and funding is available, we plan to randomise a further 28,000 subjects from seven centres in the UK. Individuals are invited to participate if they have at least 5% risk of developing lung cancer over 5 years as predicted by the LLP risk model. The “Wald Single Screen” Design has been chosen for the UKLS pilot trial. Individuals meeting the inclusion/exclusion criteria will be sent invitations to participate and selected on the basis of the LLP risk questionnaire and selected to attend one of the pilot recruitment sites. After consent has been obtained, the participant will undertake spirometry and be asked to provide specimens (of blood, oral and nasal brushings and sputum) and to complete baseline lifestyle, psychosocial, and health economic questionnaire. Participants will be randomised to the study arm and will have a single low dose computed tomography scan (CT); those in the control arm will have usual care (no CT). CT scans will be read both locally and centrally and volumetric analysis will be performed on detected nodules. Both arms will be followed up for lung cancer incidence and mortality. Mortality will be documented after 10 years of follow-up. Modelling has resulted in the development of the UKLS care pathway to manage identified nodules. The aim of the main UKLS trial is to assess whether screening by low dose CT will confer a mortality advantage of 30% and also be cost effective for the UK population. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3571. doi:1538-7445.AM2012-3571
EFFICACY AND SAFETY OF TRANSCATHETER LEFT ATRIAL APPENDAGE LIGATION WITH LARIAT: A META-ANALYSIS
Authors: Arun Kanmanthareddy, Avanija Buddam, Madhu Reddy, Muhammad Afzal, Sampath Gunda, Claire Hunter, Venkata Alla, Donita Atkins, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2015)
Improved Detection of Coronary Artery Disease by Exercise Electrocardiography with the Use of Right Precordial Leads
Authors: Andreas P. Michaelides, Zoi D. Psomadaki, Polychronis E. Dilaveris, Dimitris J. Richter, George K. Andrikopoulos, Konstantina D. Aggeli, Christodoulos I. Stefanadis, Pavlos K. Toutouzas
Journal: New England Journal of Medicine (1999)

Exercise electrocardiography is an imperfect test for the detection of coronary artery disease. We attempted to improve the diagnostic accuracy of exercise testing as a noninvasive method for the detection of coronary artery disease by using a combination of the left and right precordial leads.
Short-Term and Long-Term Survival in Patients with Alcoholic Hepatitis Treated with Oxandrolone and Prednisolone
Authors: Charles L. Mendenhall, Sharon Anderson, Pedro Garcia-Pont, Stephen Goldberg, Thomas Kiernan, Leonard B. Seeff, Michael Sorrell, Carlo Tamburro, Robert Weesner, Rowen Zetterman, Antonio Chedid, Thomas Chen, Lionel Rabin
Journal: New England Journal of Medicine (1984)

A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen per cent of the moderately ill patients and 29 per cent of the severely ill patients died. Although neither steroid improved short-term survival, oxandrolone therapy was associated with a beneficial effect on long-term survival. This was especially true in patients with moderate disease: among those who survived for one or two months after the start of treatment the conditional six-month death rate was 3.5 per cent after oxandrolone and 19 to 20 per cent after placebo (P = 0.02). No consistent long-term effect was associated with prednisolone therapy.
Abstract 238: Inhibition of SHP2 abolishes mammary tumorigenesis in mice
Authors: Fatimah Matalka, Zachary Hartman, Yehenew M. Agazie
Journal: Cancer Research (2011)

Abstract The Src homology phosphotyrosyl phosphatase 2 (SHP2) plays a positive role in receptor tyrosine kinase-induced mitogenic and cell survival signaling. In addition, SHP2 mediates cell transformation induced by oncogenic tyrosine kinases. Here, we provide evidence that show that the SHP2 protein is overexpressed in basal-type/triple-negative breast cancer (BTBC) with strong correlation to higher tumor grade, metastasis and elevated expression of the epidermal growth factor. We further show that SHP2 plays an essential role in the tumorigenesis and metastasis of BTBC cells (MDA-MB-231 and MDA-MB-468) transplanted into the mammary glands of NOD/SCID mice. These results suggest that SHP2 can be used for targeted therapy in BTBC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 238. doi:10.1158/1538-7445.AM2011-238
Liposarcoma of the Retroperitoneum With Dedifferentiation to Osteosarcoma
Authors: Linh Ho, Heidi Wassef, David Chang, William Boswell, Robert Henderson, John Seto
Journal: Clinical Nuclear Medicine (2011)

We report the F-18 FDG PET/CT appearance of a right retroperitoneal liposarcoma with dedifferentiated osteosarcoma in a 58-year-old man who presented with a right-sided abdominal mass. Staging PET/CT revealed a 9.8 × 13.3 × 17.0 cm intensely active, heterogeneous right retroperitoneal mass, with a maximum standardized uptake value of 19.6. This mass contained areas of calcification and necrosis and had displaced the right kidney anterosuperiorly. In addition, there were several subcentimeter bilateral pulmonary nodules, with minimal activity, consistent with metastatic disease. We report this case because of the rarity of liposarcoma with dedifferentiation to osteosarcoma.
The Diagnosis and Treatment of Cough
Authors: Richard S. Irwin, J. Mark Madison
Journal: New England Journal of Medicine (2000)

Cough is one of the most common symptoms for which patients seek medical attention from primary care physicians and pulmonologists,1 probably because cough can so profoundly and adversely affect the quality of patients' lives.2 In this review, we present an approach to managing cough in adults. With a systematic approach based on the guidelines we describe, it should be possible to diagnose and treat cough successfully in the great majority of cases. The cause of chronic cough can be determined in 88 to 100 percent of cases, and determination leads to specific therapies with success rates that range from 84 . . .
IMMUNOSUPPRESSIVE EFFECT OF TICAGRELOR ON DENDRITIC CELL FUNCTION: A NEW THERAPEUTIC PERSPECTIVE OF ANTIPLATELET AGENTS IN ATHEROSCLEROSIS
Authors: Yue Guo, Xiaodong Zhuang, Xun Hu, Feifei Li, Yi Li, Xinxue Liao, Zhimin Du
Journal: Journal of the American College of Cardiology (2016)
Brief Report: Lessons Learned from Studies on Tumor Suppression by Microcell-Mediated Chromosome Transfer
Authors: M. Oshimura
Journal: Environmental Health Perspectives (1991)

One approach for identifying chromosomes that carry putative tumor-suppressor genes is the introduction of individual, normal human chromosomes to the tumor cells of interest (1-4). In order to identify human chromosomes that can suppress or modulate tumor-associated phentotypes of tumor cells, we performed chromosome transfer experiments via microcell fusion into cell lines derived from a variety of tumors: neuroblastoma (SK-N-MC), fibrosarcoma (HT1080), uterine endometrial carcinoma (HHUA), renal cell carcinoma (YCR), choriocarcinoma (CC1), uterine cervical carcinoma (SiHa), rhabdomyosarcoma (A204), Wilms' tumor (SK-NEP-1), and Kirsten sarcoma virus-transformed NIH 3T3 cells (DT). We first isolated mouse A9 cells containing a single, normal human fibroblast-derived chromosome integrated with pSV2neo plasmid DNA (5). Following fusion of microcells from these A9 cells with tumor cells, we isolated microcell hybrids with the introduction of a specific chromosome and examined their tumorigenicity and in vitro properties (6-11). The following results were obtained (Table 1). The introduction of chromosome 11 suppressed tumorigenicity of HT1080, SiHa, A204, and SK-NEP-1, but not of SK-N-MC, YCR, CC1, and DT, indicating the function of the putative suppressor gene(s) on chromosome 11 is effective only in specific tumors. The tumorigenicity of YCR was modulated by the introduction of chromosome 3p, but not by chromosomes X and 11, supporting a hypothesis that loss and/or mutational inactivation of a gene on 3p may play a crucial role in the development of human renal cell carcinoma.
Abstract 845: Vascular cell adhesion molecule-1 (VCAM-1) expression in patients with ovarian tumors of low malignant potential
Authors: Melissa Henretta, Jennifer M. Scalici, Linda Duska, Jill Slack-Davis, Kristen Atkins
Journal: Cancer Research (2010)

Abstract The molecular basis for gynecologic tumor dissemination into the peritoneum is not well understood, however it is the primary mechanism of death in advanced stage ovarian cancers. Although serous borderline and serous invasive ovarian cancers are similar, they differ in their ability to implant and invade peritoneal structures. Vascular cell adhesion molecule-1 (VCAM-1), a cell surface receptor expressed on activated endothelial and mesothelial cells, regulates leukocyte attachment and extravasation at sites of inflammation. Recent studies by our group demonstrated the ability of ovarian carcinoma to induce the expression of VCAM-1 on mesothelial cells, and correlated the presence of VCAM-1 with peritoneal dissemination of the tumor. We undertook the current study to determine whether VCAM-1 is expressed on the mesothelium of patients with borderline ovarian tumors. After IRB approval was obtained, cell blocks containing peritoneum and omentum from 10 patients with borderline tumors were processed and stained using antibodies to VCAM-1. Mesothelial expression of VCAM-1 was determined by a single pathologist blinded to tumor type and stage. Samples were determined to be positive if mesothelial cells demonstrated membrane staining. Cytoplasmic staining for VCAM-1 was not considered positive, nor was staining of non-mesothelial cells. Of the 10 patients, four were stage 1a and six were stage 1c serous borderline tumors. Nine of 10 had peritoneal or omental biopsies that did not stain for VCAM-1. The one sample which did stain positively was micropapillary type, which is an invasive sub-type of borderline ovarian cancers. Together, these observations support the hypothesis that VCAM-1 expression correlates with ovarian cancer peritoneal invasion and offers a possible explanation for the inability of borderline tumors to invade peritoneal structures. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 845.
285 DOWNREGULATION OF ORGANIC CATION TRANSPORTERS OCT1 (SLC22A1) AND OCT3 (SLC22A3) IN HUMAN HEPATOCELLULAR CARCINOMA AND THEIR PROGNOSTIC SIGNIFICANCE
Authors: J. Knapstein, M. Heise, A. Lautem, J. Schattenberg, P.R. Galle, G. Otto, M. Schuchmann, T. Zimmermann
Journal: Journal of Hepatology (2012)
AB1050 Rentability of second percutaneous disco-vertebral biopsy (PDVB) in case of infectious spondylodiscitis (ISD)
Authors: A. Carcasses, A. Elsendoorn, R. Brault, F. Roblot, F. Debiais
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> When ISD is suspected, a second PDVB can be realised if the first analysis is negative. The rentability of this medical procedure remains insufficiently studied. <h3>Objectives</h3> The study's objective was to evaluate the benefit of a second PDVB. <h3>Methods</h3> This retrospective study included all patients hospitalised for ISD between 2005 and 2011 in the department of Rheumatology and Department of Infectious Diseases and Immunity for whom blood cultures and the first PDVB was negatives and who have had a second PDVB. For each patient we analysed clinical characteristics et microbiologics results. <h3>Results</h3> One hundred and twenty four ISD were diagnosed during this period. The blood culture and the first PDVB remained negatives for 22 patients (18%). Among them, 6 had only one sample positive with commensal germ considerate as non pathogenic. Fourteen patients (11 men, 3 women, medium age 58 years (±13)) have had a second PDVB. The intervertebral localisation of ISD was lumbar (11 cases), cervical (2 cases) or thoracic (1 case). It was post operative ISD in 11 cases (79%). Results of second PDVB are: negatives in 8 cases, identification of microorganism considered as non pathogenic in 2 cases (<i>propionibacterium acnes and ruminococcus productus</i>); identification of the same microorganism as the one found in the first PDVB in 3 cases (<i>staphylococcus epidermidis, Propionibacterium acnes et Staphylococcus caprae</i>); identification of <i>Staphylococcus saccharolyticus</i> in 2 differents samples in 1 case. <h3>Conclusions</h3> The second PDVB was contributive for the microbiologic diagnosis in 4 cases of 14 (29%). Bacteria revealed by the second PDVB were all commensal bacteria responsive to probabilist antibiotherapy such as recommanded by consensus conference. <h3>Disclosure of Interest</h3> None Declared.
Case 12-1965
Authors: Charles S. Davidson, Benjamin Castleman
Journal: New England Journal of Medicine (1965)

Presentation of Case*A fifty-three-year-old man was admitted to the hospital because of jaundice.He had been well until three weeks previously, when nausea, weakness and intermittent vomiting developed. During the next ten days he experienced several shaking chills, with elevation of the temperature to 104°F., and episodes of mild epigastric pain, generally after vomiting. The urine was dark, but the stools were of a normal color. Ten days before admission he entered another hospital; icterus was observed, and he was treated with a liquid diet and fluids administered intravenously. The fever persisted, nocturnal confusion occurred, and the jaundice increased . . .
Case 34-2005
Authors: Robert L. Sheridan, Vincent Liu, Sudha Anupindi
Journal: New England Journal of Medicine (2005)

A rash developed in a 10-year-old girl and became confluent and bullous, with sloughing, after she was given carbamazepine for a seizure. Oral and conjunctival sloughing followed, with pancytopenia, gastrointestinal hemorrhage, and respiratory failure. After a protracted course of management in the burn unit, reepithelialization occurred, and the patient recovered fully.
SERUM URIC ACID LEVEL AND PREVALENCE OF ATRIAL FIBRILLATION IN 285,882 JAPANESE GENERAL POPULATION
Authors: Shin Kawasoe, Shiro Yoshifuku, Takuro Kubozono, Hironori Miyahara, Naoya Oketani, Masaaki Miyata, Shigeho Maenohara, Mitsuru Ohishi
Journal: Journal of the American College of Cardiology (2015)
Abstract 1874: Public health impact of occupational carcinogens exposure and lung cancer
Authors: Sara De Matteis, Dario Consonni, Jay H. Lubin, Sholom Wacholder, Margaret Tucker, Susan Peters, Roel C. H. Vermeulen, Hans Kromhout, Pier Alberto Bertazzi, Neil Caporaso, Angela Cecilia Pesatori, Maria Teresa Landi
Journal: Cancer Research (2011)

Abstract Background. Exposure to occupational carcinogens is an important preventable cause of lung cancer. Most previous studies were in highly exposed industrial cohorts. Our aim was to quantify lung cancer burden attributable to occupational carcinogens in a general population. Methods. We estimated lung cancer risk associated with occupational carcinogens using a new validated job-exposure matrix (JEM), in the Environment And Genetics in Lung cancer Etiology (EAGLE) study, a large (2100 cases and 2120 controls) population-based case-control study conducted in Lombardy, Italy, between 2002-2005. The JEM translated lifetime work-histories coded into standard job-titles into never, low, and high exposure levels for six known/suspected occupational lung carcinogens. We calculated odds ratios (OR) and 95% confidence intervals (CI) in men (1537 cases and 1617 controls), by multiple logistic regression, adjusted for potential confounders, e.g., tobacco smoking and co-exposure to JEM carcinogens. We estimated the Population Attributable Fraction (PAF) as impact measure. Results. Exposure to asbestos (OR=1.76, 95%CI=1.42 to 2.18), crystalline silica (OR=1.31, 95%CI=1.00 to 1.71), or nickel-chromium (OR=1.18, 95%CI=0.90 to 1.53) was associated with increased risk even at low exposures, with positive trends for intensity and duration. We found an excess risk for exposure to polycyclic aromatic hydrocarbons only among highly exposed workers (OR=1.64, 95%CI=0.99 to 2.70). The PAFs for any exposure to asbestos, crystalline silica and nickel-chromium were 18.1%, 5.7%, and 7.0%, respectively, corresponding to ≈300-800 lung cancer cases/year. Conclusion. These findings support the substantial role of selected occupational carcinogens on lung cancer burden, even in a low exposed general population. Health policy interventions are warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1874. doi:10.1158/1538-7445.AM2011-1874
Abstract 1307: Downregulation of vascular endothelial cell growth inhibitor (VEGI; TNFSF15) expression in endothelial cells by interferon-γ
Authors: Yi Lu, Li Chen, Lu-Yuan Li
Journal: Cancer Research (2010)

Abstract Vascular endothelial growth inhibitor (VEGI) is a member of the tumor necrosis factor superfamily (TNFSF15) produced largely by endothelial cells. It functions as an endogenous inhibitor of neovascularization. We showed previously that VEGI inhibits angiogenesis by enforcing a growth arrest on quiescent endothelial cells while inducing apoptosis in proliferating endothelial cells. We also found that VEGI gene expression is down-regulated in growing endothelial cells in vitro as well as in tumor vasculatures. Here we show that, among a variety of inflammation-modulating cytokines we evaluated, interferon-γ (IFNγ) can down-regulate VEGI expression in human umbilical vein endothelial cells in a dose- and time-dependent manner. Neutralizing antibodies of IFNγ receptor 1 restores VEGI expression. IFNγ modulation of VEGI gene expression is mediated by unphosphorylated STAT1 rather than phosphorylated STAT1. These findings are consistent with the view that down-regulation of VEGI gene expression in endothelial cells by IFNγ is a prerequisite for the initiation and continuation of angiogenesis during inflammation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1307.
Case 20-2005
Authors: David P. Ryan, Carlos Fernandez-del Castillo, Christopher G. Willett, William R. Brugge, Dushyant Sahani, Elena F. Brachtel
Journal: New England Journal of Medicine (2005)

A 58-year-old man was being evaluated for an abdominal aortic aneurysm when a pancreatic mass was incidentally found; in retrospect, he had experienced vague abdominal discomfort and weight loss for several months. Further evaluation disclosed a pancreatic adenocarcinoma that encased the superior mesenteric and portal veins. Treatment options are discussed.